Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07650266 · ClinicalTrials.gov registry record · Phase 1
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Not yet
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT07650266: Clinical Trial Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT07650266 is a Phase 1 study that has not yet begun recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07650266, a Phase 1 study, has not yet begun recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.
Primary Outcome
To determine the post-induction complete response rate in participants treated with induction gemcitabine/cisplatin/cemiplimab with or without fianlimab prior to personalized chemoradiation for locoregionally advanced non-metastatic NPC
Interventions
- DRUG Cemiplimab
- DRUG Fianlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-07 |
| Phase | Phase 1 |
What is known before NCT07650266 opens enrollment
NCT07650266 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Cemiplimab is the first listed.
NCT07650266 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07650266 about?
NCT07650266 is a clinical study titled "A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma". The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.
What is the current status of trial NCT07650266?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-07. Estimated completion is 2030-07.
What interventions are being tested in trial NCT07650266?
The interventions under investigation include: Cemiplimab (DRUG), Fianlimab (DRUG).
Who is sponsoring clinical trial NCT07650266?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07650266's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia